Oral management of scabies | Single-dose rapid IV iron replacement | New opioid for chronic pain

What’s new in NPS RADAR August 2014?
 
Having trouble viewing this email? View as web page
Twitter   Google+   LinkedIn   YouTube
RADAR NPS RADAR
AUGUST 2014
NPS MEDICINEWISE
RADAR ‘up-GRADE’
In this issue we introduce a further enhancement to the evidence appraisal of new drugs in the form of the GRADE systematic evaluation of the quality of evidence.
Read more about GRADE  >
Full Reviews
 
Scabies mite
Scabies mite
Ivermectin (Stromectol) for typical and crusted scabies
Ivermectin (Stromectol) is an orally dosed treatment for scabies that was recently given TGA approval and is now PBS listed for the treatment of typical and crusted scabies.
Where does ivermectin fit in treatment?  >
 
Red blood cells
Red blood cells
Ferric carboxymaltose (Ferinject) for iron-deficiency anaemia
Ferric carboxymaltose (Ferinject) is the fourth parenteral iron preparation to be PBS listed. It can rapidly correct iron-deficiency anaemia across a range of clinical conditions, with efficacy and tolerability similar to those of IV iron sucrose and superior to those of oral iron supplementation.
Compare with other iron-replacement options  >
 
Osteoarthritic knee
Osteoarthritic knee
Tapentadol sustained release (Palexia SR) for chronic, severe disabling pain
Tapentadol SR is a centrally acting opioid analgesic for chronic, severe disabling pain not responding to non-opioid analgesics. Studies have shown it may have similar efficacy to that of oxycodone CR for the relief of chronic pain associated with osteoarthritis and low back pain. There are currently limited data regarding other chronic pain conditions, and limited comparative data with other opioids, including tramadol.
What is tapentadol’s place in therapy?  >
 
In Brief
A digest of news items about new drugs and medical tests, changes to PBS listings, and updates of past NPS RADAR reviews.
Aclidinium (Bretaris Genuair) for chronic obstructive pulmonary disease
More than just evidence summaries — rating the quality of evidence with GRADE
 
Health news & evidence and NPS Direct
Tell us
Tell us what you think
We’d love to hear your views – please take a moment to give us feedback.
Connect with us
Twitter Google+ LinkedIn YouTube
Message Share with your peers by forwarding this email.
Message  
 
 
Medicines
Dotted
Antibiotics
Dotted
Antidepressants
Dotted
Vaccines & immunisation
Dotted
Warfarin
Dotted
See more
Dotted
Health topics
Dotted
Ages & life stages
Dotted
Managing medicines
Dotted
Preventive health
Dotted
Multiple medicines
Dotted
See more
Dotted
Conditions
Dotted
Sore throat
Dotted
Common cold
Dotted
Asthma
Dotted
Type 2 diabetes
Dotted
See more
Dotted
Health professionals
Dotted
CPD & learning
Dotted
Health news & evidence
Dotted
Patient fact sheets
Dotted
Medicine resources
Dotted
See more
Dotted
 
Medical tests
Dotted
Blood tests
Dotted
Pathology
Dotted
Medical imaging
Dotted
X-rays
Dotted
See more
Dotted
Publications
Dotted
Australian Prescriber
Dotted
Medicinewise Living
Dotted
NPS Direct
Dotted
NPS RADAR
Dotted
See more
Dotted
 
Dotted
   
 
 
   
Dotted
   
 
 
   
Dotted
   
 
 
   
Dotted
   
 
 
   
Dotted
   
 
 
   
Dotted
   
 
 
   
Dotted
Image credits:
Ivermectin: O’Kelly & Associates | Ferric carboxymaltose: kpuljek/shutterstock | Tapentadol: decade3d/shutterstock

This email has been sent to you from NPS MedicineWise.

© 2014 National Prescribing Service Limited. ABN 61 082 034 393. Independent, not-for-profit and evidence based, NPS MedicineWise enables better decisions about medicines and medical tests. We are funded by the Australian Government Department of Health. National Prescribing Service Limited trading as NPS MedicineWise. Head office: Level 7, 418A Elizabeth Street, Surry Hills 2010 NSW.

 
Pledge to join the fight against antibiotic resistance
 
Update my details | Subscribe |  
[email protected]” target=”_blank” style=”color: rgb(53, 59, 79);”>Unsubscribe | Privacy | Contact us
 

0 回復

發表評論

Want to join the discussion?
Feel free to contribute!

發表迴響

你的電子郵件位址並不會被公開。 必要欄位標記為 *